Inspire Medical Systems, Inc. (INSP) Stock Analysis

Inspire Medical Systems, Inc. (INSP) Stock Analysis

Overall Grade: F (Concerning)

View interactive company profile →

Inspire Medical Systems, Inc. faces challenges in financial performance that warrant careful analysis.

Key Metrics:

Metric Value Context
ROIC 4.7% Below expectations
FCF Margin 11.2% Healthy cash flow
Debt/Equity 0.0x Conservative leverage

Investment Thesis: Healthy free cash flow margin of 11.2% provides financial flexibility for growth and shareholder returns.


What is Inspire Medical Systems, Inc.'s Profitability and ROIC?

Inspire Medical Systems, Inc.'s return on invested capital of 4.7% is below the typical cost of capital. Gross margin of 84.9% with operating margin at 4.2% reflects the company's strong market position.

Key Metrics

Metric Value Rating Interpretation
Return on Invested Capital (ROIC) 4.7% Warning Below cost of capital
Return on Equity (ROE) 6.6% Warning Moderate equity returns
Gross Margin 84.9% Excellent Strong pricing power
Operating Margin 4.2% Warning Moderate operational efficiency

How Strong is Inspire Medical Systems, Inc.'s Cash Flow Quality?

Inspire Medical Systems, Inc. generated $98.8M in free cash flow over the trailing twelve months, representing a 11.2% margin. Cash earnings quality is strong, with operating cash flow exceeding net income by 3.0x.

Key Metrics

Metric Value Rating Interpretation
Free Cash Flow Margin 11.2% Good Healthy cash generation
Free Cash Flow (TTM) $98.8M Good Positive cash generation
OCF/Net Income 3.0x Excellent High earnings quality
FCF Consistency (8Q) N/A Warning Variable cash flow

What is Inspire Medical Systems, Inc.'s Financial Health?

Inspire Medical Systems, Inc.'s debt-to-equity ratio of 0.0x indicates conservative leverage.

Key Metrics

Metric Value Rating Interpretation
Debt to Equity 0.0x Excellent Conservative capital structure

Is Inspire Medical Systems, Inc. Stock Overvalued or Undervalued?

Inspire Medical Systems, Inc. trades at a P/E of 49.1x, representing a premium to the sector median of N/A. Free cash flow yield of 4.5% reflects market expectations for growth.

Key Metrics

Metric Value Rating Interpretation
P/E Ratio 49.1x Adequate Premium valuation
EV/Sales 4.8x Good Growth premium priced in
FCF Yield 4.5% Good Lower cash yield

Sector Rankings

Metric Value Percentile vs Median
Return on Invested Capital (ROIC) 4.7% Top 50% -
Free Cash Flow Margin 11.2% Top 25% -
Gross Margin 84.9% Top 25% 1.4x above
Operating Margin 4.2% Bottom 50% 0.9x below
Return on Equity (ROE) 6.6% Top 50% -
P/E Ratio 49.1x N/A -

Rating Thresholds

Return on Invested Capital (ROIC)

Measures how efficiently a company uses its debt and equity capital to generate profits. ROIC above 15% typically indicates a competitive moat.

Rating Range Interpretation
Excellent > 20% Exceptional capital efficiency, strong competitive moat
Good 12% - 20% Above-average returns, sustainable competitive position
Adequate 8% - 12% Around cost of capital, moderate competitive position
Warning 4% - 8% Below cost of capital, value may be eroding
Red flag < 4% Significant capital destruction, fundamental issues

Current: 4.7% (Warning - Top 50% of sector (median: 0.0%))

Free Cash Flow Margin

The percentage of revenue converted to free cash flow. Higher margins indicate stronger cash generation and business quality.

Rating Range Interpretation
Excellent > 20% Strong cash generation, high-quality business
Good 10% - 20% Healthy cash conversion
Adequate 5% - 10% Moderate cash generation
Warning 0% - 5% Thin cash margins, capital intensive
Red flag < 0% Cash burn, potential liquidity concerns

Current: 11.2% (Good - Top 25% of sector (median: 0.0%))

Gross Margin

Revenue minus cost of goods sold as a percentage. Higher gross margins indicate pricing power and competitive advantage.

Rating Range Interpretation
Excellent > 50% Strong pricing power and competitive moat
Good 30% - 50% Healthy margins, differentiated product
Adequate 20% - 30% Moderate margins, competitive industry
Warning 10% - 20% Thin margins, commodity-like business
Red flag < 10% Very thin margins, structural challenges

Current: 84.9% (Excellent - Top 25% of sector (median: 61.4%))

Debt to Equity Ratio

Total debt divided by shareholders' equity. Lower ratios indicate more conservative financing and reduced financial risk.

Rating Range Interpretation
Excellent < 0.3x Conservative leverage, strong balance sheet
Good 0.3x - 0.7x Moderate leverage, healthy financial position
Adequate 0.7x - 1.5x Elevated leverage, monitor closely
Warning 1.5x - 3.0x High leverage, increased financial risk
Red flag > 3.0x Excessive leverage, potential distress risk

Current: 0.0% (Excellent)

P/E Ratio (Price-to-Earnings)

Stock price divided by earnings per share. Lower P/E may indicate undervaluation, while higher P/E suggests growth expectations.

Rating Range Interpretation
Excellent < 15x Attractively valued, potential opportunity
Good 15x - 25x Fair value for quality company
Adequate 25x - 35x Growth premium, justify with earnings growth
Warning 35x - 50x High expectations priced in
Red flag > 50x or negative Speculative valuation or losses

Current: 49.1x (Adequate)

Free Cash Flow Yield

Free cash flow per share divided by stock price. Higher FCF yield indicates better cash return relative to valuation.

Rating Range Interpretation
Excellent > 8% High cash return, potential value opportunity
Good 5% - 8% Solid cash yield
Adequate 3% - 5% Moderate cash return
Warning 1% - 3% Low cash yield, growth expectations
Red flag < 1% Minimal cash return to shareholders

Current: 4.5% (Adequate)


Frequently Asked Questions

Q: What is Inspire Medical Systems, Inc.'s Return on Invested Capital (ROIC)?

Inspire Medical Systems, Inc. (INSP) has a trailing twelve-month Return on Invested Capital (ROIC) of 4.7%. This compares above the sector median of 0.0%. An ROIC below 8% suggests the company may be destroying shareholder value.

Q: What is Inspire Medical Systems, Inc.'s Free Cash Flow Margin?

Inspire Medical Systems, Inc. (INSP) has a free cash flow margin of 11.2%, generating $98.8 million in free cash flow over the trailing twelve months. A FCF margin between 10-20% represents healthy cash generation for most industries.

Q: Is Inspire Medical Systems, Inc. stock overvalued or undervalued?

Inspire Medical Systems, Inc. (INSP) trades at a P/E ratio of 49.1x, which is above the sector median of N/A. The EV/Sales multiple is 4.8x. Free cash flow yield is 4.5%, which is in line with market averages.

Q: What is Inspire Medical Systems, Inc.'s revenue and earnings growth?

Inspire Medical Systems, Inc. (INSP) grew revenue by 16.8% year-over-year. Earnings per share increased by 34.9% compared to the prior year. Solid growth above 10% suggests healthy business momentum.

Q: Is Inspire Medical Systems, Inc. buying back stock?

Inspire Medical Systems, Inc. (INSP) repurchased $200.0 million of stock over the trailing twelve months. This represents a buyback yield of 9.1%.

Q: How does Inspire Medical Systems, Inc. compare to competitors in Healthcare?

Compared to other companies in Healthcare, Inspire Medical Systems, Inc. (INSP) shows: ROIC of 4.7% is above the sector median of 0.0% (Top 40%). FCF margin of 11.2% exceeds the sector median of 0.0% (Top 14% of sector). Gross margin at 84.9% is 23.6 percentage points higher than sector peers. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with Inspire Medical Systems, Inc.?

Inspire Medical Systems, Inc. (INSP) shows no major financial warning signs based on current metrics. However, investors should always monitor: 1) Margin compression trends, 2) Cash flow consistency, 3) Debt levels relative to cash generation, and 4) Changes in competitive positioning.


Data Source: Data sourced from 10-Q filed 2025-11-03. TTM metrics as of Q3 2025.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

This analysis is for informational purposes only and does not constitute investment advice.